Sunitinib surpasses standard therapy for metastatic renal cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1544, 2006-01, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Temsirolimus tops standard therapy for advanced renal cancer

Inpharma, Vol. 1, Iss. 1542, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer

Current Cancer Drug Targets, Vol. 12, Iss. 6, 2012-07 ,pp. : 693-702

Bentham Science Publishers

Access to resources Recommend Favorite

Sunitinib cost effective for renal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Sunitinib soars ahead in renal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Superior QOL with sunitinib in renal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 560, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite